I’m reposting this because I think that this is an important article. The full article is
available for free at pubmed.gov (see attachment if it posts on the list serve)
It’s authored by 32 members of an international cancer research group,
working as part of the “Halifax Project”.
They came up with 10 prototypical phytochemical compounds to both treat and
prevent cancer. Five of the ten are already in my cocktail: silibinin (milk thistle),
epigallocatechin-gallate (green tea), curcumin, melatonin and resveratrol.
I’m currently looking up sources for the other compounds…
oleic acid is found in olive oil,
tripterine is found in a Chinese herb (thunder god vine),
kaempferol is found in canned capers
enterlactone 7-HMR lignans SWU334 60 40mg caps $ 14.99 (swanson’s)
withaferin A is found in the Chinese (winter cherry)
Deregulation ofangiogenesis – the growth of new blood vessels from an existing vasculature -is a main driving force in many severe human diseases including cancer. Assuch, tumor angiogenesis is important for delivering oxygen and nutrients togrowing tumors, and therefore considered an essential pathologic feature ofcancer, while also playing a key role in enabling other aspects of tumorpathology such as metabolic deregulation and tumor dissemination/metastasis.Recently, inhibition of tumor angiogenesis has become a clinical anti-cancerstrategy in line with chemotherapy, radiotherapy and surgery, which underscorethe critical importance of the angiogenic switch during early tumordevelopment. Unfortunately the clinically approved anti-angiogenic drugs in usetoday are only effective in a subset of the patients, and many who initiallyrespond develop resistance over time. Also, some of the anti-angiogenic drugsare toxic and it would be of great importance to identify alternativecompounds, which could overcome these drawbacks and limitations of thecurrently available therapy. Finding “the most important target” may,however, prove a very challenging approach as the tumor environment is highlydiverse, consisting of many different cell types, all of which may contributeto tumor angiogenesis. Furthermore, the tumor cells themselves are geneticallyunstable, leading to a progressive increase in the number of differentangiogenic factors produced as the cancer progresses to advanced stages. As analternative approach to targeted therapy, options to broadly interfere withangiogenic signals by a mixture of non-toxic natural compound with pleiotropicactions were viewed by this team as an opportunity to develop a complementaryanti-angiogenesis treatment option. As a part of the “HalifaxProject” within the “Getting to know cancer” framework, we havehere, based on a thorough review of the literature, identified 10 importantaspects of tumor angiogenesis and the pathological tumor vasculature whichwould be well suited as targets for anti-angiogenic therapy: (1) endothelialcell migration/tip cell formation, (2) structural abnormalities of tumorvessels, (3) hypoxia, (4) lymphangiogenesis, (5) elevated interstitial fluidpressure, (6) poor perfusion, (7) disrupted circadian rhythms, (8) tumorpromoting inflammation, (9) tumor promoting fibroblasts and (10) tumor cellmetabolism/acidosis. Following this analysis, we scrutinized the availableliterature on broadly acting anti-angiogenic natural products, with a focus onfinding qualitative information on phytochemicals which could inhibit thesetargets and came up with 10 prototypical phytochemical compounds: (1) oleicacid, (2) tripterine, (3) silibinin, (4) curcumin, (5)epigallocatechin-gallate, (6) kaempferol, (7) melatonin, (8) enterolactone, (9)withaferin A and (10) resveratrol. We suggest that these plant-derivedcompounds could be combined to constitute a broader acting and more effectiveinhibitory cocktail at doses that would not be likely to cause excessivetoxicity. All the targets and phytochemical approaches were furthercross-validated against their effects on other essential tumorigenic pathways(based on the “hallmarks” of cancer) in order to discover possiblesynergies or potentially harmful interactions, and were found to generally alsohave positive involvement in/effects on these other aspects of tumor biology.The aim is that this discussion could lead to the selection of combinations ofsuch anti-angiogenic compounds which could be used in potent anti-tumorcocktails, for enhanced therapeutic efficacy, reduced toxicity andcircumvention of single-agent anti-angiogenic resistance, as well as forpossible use in primary or secondary cancer prevention strategies.
Copyright ©2015 The Authors. Published by Elsevier Ltd.. All rights reserved.
[PubMed – as supplied by publisher]
Free full text